drugset / Trial / NCT00511082
Phase 1 Study of OPB-31121 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Phase 1
Completed
7 enrolled
Otsuka Beijing Research Institute
Otsuka Pharmaceutical Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
* To investigate the safety and tolerability of OPB-31121 following repeated oral administration of OPB-31121 in patients Non-Hodgkin's Lymphoma(NHL) or Multiple Myeloma(MM) * To determine the potential dose-limiting toxicities and maximum-tolerated dose in patients treated with OPB-31121 * To determine the pharmacokinetics and anti-tumor efficacy of OPB-31121 in patients
Timeline
- Start
- 2007-12
- Primary completion
- 2009-12
- Completion
- 2010-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OPB-31121 | Unknown | 50 mg | Oral |
| Subject | OPB-31121 | Unknown | 100 mg | Oral |
| Subject | OPB-31121 | Unknown | 200 mg | Oral |
| Subject | OPB-31121 | Unknown | 400 mg | Oral |
| Subject | OPB-31121 | Unknown | 600 mg | Oral |
| Subject | OPB-31121 | Unknown | 800 mg | Oral |
| Subject | OPB-31121 | Unknown | 1000 mg | Oral |